Tango Therapeutics
TNGX | NASDAQ
$24.17
-$1.33 (-5.22%)
At close: Nov 16, 2026, 4:00 PM ET
$24.22
+$0.05 (+0.21%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tango Therapeutics Company Profile
Company profile explainedCompany Profile
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Malte Peters | President, Chief Executive Officer & Director |
| Matthew Gall | Chief Financial Officer |
| Adam S. Crystal | President of Research & Development |
| Alan Ashworth | Founder & Member of Scientific Advisory Board |
| Antoni Ribas | Founder & Member of Scientific Advisory Board |
| Barbara L. Weber | Executive Officer |
| Daniella Beckman | Executive Officer |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications |
| Janice Kapty | Senior Vice President of Corporate Strategy & Project Leadership |
| Jannik N. Andersen | Chief Scientific Officer |
| Julie Carretero | Chief Human Resources Officer |
| Julie Fogarty | Senior VP, General Counsel & Corporate Secretary |
| Philippe Serrano | Chief Regulatory Officer |
| William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board |
| Yen-Ching Chua | Chief Development Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Tango Therapeutics
| Country | United States |
| IPO Date | Sep 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Malte Peters |
Contact Details
201 Brookline Avenue Boston,
Massachusetts 02215 United States
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| SIC Code | 2834 |
Recent News
- 8 days ago / globenewswire.comTango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
- 14 days ago / globenewswire.comTango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
- 19 days ago / seekingalpha.comTango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
- 22 days ago / zacks.comTNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
- 24 days ago / seekingalpha.comTango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
- 25 days ago / marketbeat.comTango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
- 25 days ago / benzinga.comWhy Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
- 25 days ago / investors.comTango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
- 25 days ago / globenewswire.comTango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
- 2 months ago / zacks.comWhy Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Add to Watchlist
Select watchlists to add or remove TNGX